HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.

Abstract
Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of peripheral T-cell lymphomas with a poor prognosis. Autologous stem cell transplantation (ASCT) was retrospectively evaluated as a consolidation or salvage strategy for EATL. The analysis included 44 patients who received ASCT for EATL between 2000 and 2010. Thirty-one patients (70%) were in first complete or partial remission at the time of the ASCT. With a median follow-up of 46 months, relapse incidence, progression-free survival, and overall survival were 39%, 54%, and 59% at 4 years, respectively, with only one relapse occurring beyond 18 months posttransplant. There was a trend for better survival in patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062). ASCT is feasible in selected patients with EATL and can yield durable disease control in a significant proportion of the patients.
AuthorsEsa Jantunen, Ariane Boumendil, Herve Finel, Jian-Jian Luan, Peter Johnson, Alessandro Rambaldi, Andrew Haynes, Michel A Duchosal, Wolfgang Bethge, Pierre Biron, Kristina Carlson, Charles Craddock, Claudius Rudin, Jurgen Finke, Gilles Salles, Frank Kroschinsky, Anna Sureda, Peter Dreger, Lymphoma Working Party of the EBMT
JournalBlood (Blood) Vol. 121 Issue 13 Pg. 2529-32 (Mar 28 2013) ISSN: 1528-0020 [Electronic] United States
PMID23361910 (Publication Type: Evaluation Study, Journal Article)
Topics
  • Adult
  • Aged
  • Enteropathy-Associated T-Cell Lymphoma (diagnosis, mortality, therapy)
  • Female
  • Germany (epidemiology)
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Male
  • Medical Oncology (organization & administration)
  • Middle Aged
  • Retrospective Studies
  • Societies, Medical
  • Survival Analysis
  • Transplantation, Autologous
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: